Skip to content

In-line Filters on ICU

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02281604
Enrollment
3281
Registered
2014-11-03
Start date
2013-01-31
Completion date
2018-12-31
Last updated
2019-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Micropore Filters

Brief summary

The purpose of this study is to determine whether the use of 0.2/1.2 microliter in-line filter reduces the incidence of severe vasoplegia comparing to the 5 microliter filter.

Interventions

None listed

Sponsors

Johann Wolfgang Goethe University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* all patients

Exclusion criteria

* Younger than 18 years

Design outcomes

Primary

MeasureTime frame
Incidence of severe vasoplegiaparticipants will be followed for the duration of intensive care unit stay, an expected average of 1 week

Secondary

MeasureTime frameDescription
Organ dysfunctionparticipants will be followed for the duration of intensive care unit stay, an expected average of 1 weekSeverity of organdysfunction (SOFA-Score), incidence and severity of respiratory failure (Horovitz- Index), incidence and severity of acute kidney failure (RIFLE criteria), incidence and severity of delirium
Inflammationparticipants will be followed for the duration of intensive care unit stay, an expected average of 1 weekInterleukin-6
Duration of ICU and hospital stayparticipants will be followed for the duration of intensive care unit/ hospital stay, an expected average of 1 or 4 week (s), respectively
In-hospital mortalityparticipants will be followed for the duration of hospital stay, an expected average of 4 weeks
Morbidityparticipants will be followed for the duration of hospital stay, an expected average of 4 weeksIncidence of preoperative myocardial infarction, stroke, pneumonia, sepsis and acute kidney failure according to routine documentation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026